A CME/AAFP, ABIM MOC Activity

TO REGISTER
Click here to complete your registration.


If you will be watching the webinar in a group setting, please note all group participants will need to register individually in order to complete the post-test and evaluation to receive credit.

DATES AND TIMES

AGENDA
Welcome and Introduction
Detecting Mild Cognitive Impairment and Decline Early in the Course of Disease
Current and Emerging Therapies for AD
Q & A Session and Activity Roundup

PROGRAM DESCRIPTION
With the number of Alzheimer’s disease (AD) specialists limited in many parts of the country, many primary care physicians (PCPs) must provide care, often beyond their level of training or expertise, for patients with AD or early signs of AD. Too often early signs and symptoms of AD are missed or not given appropriate priority, and thus specialty referrals occur later in the course of disease. Furthermore, the difficulty in diagnosing AD and the lack of any disease modifying therapy (DMT) for AD has fostered clinical inertia among many physicians. However, the approval of the first blood test for AD in November 2020 and the first DMT, aducanumab, in June 2021, should begin to provide the armamentarium that has been missing from AD management since it was first characterized.

Given that 85% of initial AD diagnoses are made by non-specialists, yet almost 40% of PCPs are not comfortable making the diagnosis and 50% do not consider medical professionals prepared to care for people with AD, it is vital that PCPs receive education to help them stay abreast of these recent developments, be able to integrate them into practice where appropriate and in an evidence-based manner, and be aware of emerging developments in AD diagnosis and treatment.

The educational program, “A NEW DAWN IN ALZHEIMER’S DISEASE MANAGEMENT: Recent Advances in Diagnosis and Treatment” will provide the latest AD clinical developments in a manner that is most relevant to the primary care setting and will provide access to AD resources and experts to help prepare them for the potential sea change in AD management. 

STEERING COMMITTEE

Sharon Cohen, MD, FRCPC
Neurologist and Medical Director
Toronto Memory Program
Toronto, Canada

R. Scott Turner, MD, PhD
Professor of Neurology and Director, Memory Disorders Program
Georgetown University Medical Center
Washington, DC


 


TARGET AUDIENCE
The intended audience for this educational initiative is primary care physicians and other clinicians who manage patients with AD and other dementias.

EDUCATIONAL OBJECTIVES
At the conclusion of this activity, participants should be able to:

• Integrate validated assessment tools and discuss available biomarker testing to diagnose Alzheimer’s disease early in the course of disease
• Make timely and appropriate referrals to AD specialists for patients with symptoms of AD or other dementias
• Assess the safety and efficacy profiles of current and emerging treatment options for Alzheimer’s disease

PHYSICIAN ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION STATEMENT
The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For questions regarding CME credit or the evaluation, please email contact@potomacme.org.

ABIM MOC RECOGNITION STATEMENT
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

To receive CME credit and/or MOC points, you MUST pass the post-test and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through PCME’s ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

ABMS MOC APPROVAL STATEMENT
Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Continuing Certification Activities through the ABMS Continuing Certification Directory, A NEW DAWN IN ALZHEIMER'S DISEASE MANAGEMENT: Recent Advances in Diagnosis and Treatment has met the requirements as a Part II CME Activity (apply toward general CME requirement) for the following ABMS Member Boards:

ABMS MOC Part II CME Activity
Family Medicine

AAFP CREDIT DESIGNATION STATEMENT
The AAFP has reviewed A NEW DAWN IN ALZHEIMER’S DISEASE MANAGEMENT: Recent Advances in Diagnosis and Treatment, and deemed it acceptable for AAFP credit. Term of approval is from 02/03/2022 to 06/30/2022. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This session is approved for 1 Live AAFP Prescribed credit.

DISCLOSURE INFORMATION
Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other relevant professional organizations, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of an accredited continuing education program provided by the Potomac Center for Medical Education are required to disclose to PCME all financial relationships with any ineligible company within the past 24 months. All financial relationships reported are identified as relevant and mitigated by PCME in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of the activity is vetted by PCME to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships will be mitigated by PCME.

Disclosure and mitigation information will be made known to the participants prior to the start of the activity.

FDA DISCLOSURE
The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

SYSTEM CHECK
To ensure your computer is compatible for the live event, please perform a system check by clicking on the link http://livewebcast.net/test or by typing it into your internet browser. Please perform the system check on the same computer you will use for the live event. If your computer is compatible, you will receive a confirmation message on your screen and hear audio. Otherwise, please contact the Help Desk to resolve any issues.

HARDWARE REQUIREMENTS
WINDOWS

• 1.4 GHz Intel Pentium 4 or faster processor (or equivalent)
• Windows 10, 8.1 (32-bit/64-bit), Windows 7 (32-bit/64-bit)
• 512 MB of RAM (1 GB recommended)
• Microsoft Internet Explorer 11 or later, Windows Edge browser, Mozilla Firefox, and Google Chrome
• For HTML Client - Google Chrome (v70.0 & above), Mozilla Firefox (v65.0 & above), and Edge (v42.0 & above)

MAC OS

• 1.83 GHz Intel Core Duo or faster processor
• 512 MB RAM (1 GB recommended)
• Mac OS X 10.12, 10.13 and 10.14
• Mozilla Firefox, Apple Safari, Google Chrome
• For HTML Client - Google Chrome (v70.0 & above), Apple Safari (v12.0 & above), and Mozilla Firefox (v65.0 & above)

MOBILE

• The Adobe Connect app for iOS and Android requires Adobe Connect Server version 8.2 or later
• Some features may not be enabled in all Adobe Connect meetings if one is using an Adobe Connect Server older than version 9.4.2 (required for Custom pods)
• Google Android 4.4 or later
• Apple iOS: iOS 8.1.2 or later

SOFTWARE REQUIREMENTS
DSL/cable (wired connection recommended)

INSTRUCTIONS FOR PARTICIPANTS AND OBTAINING CME CREDIT AND MOC POINTS
There is no fee for this activity. To receive credit, participants must register, view the live CME/MOC activity in its entirety, and then complete the post-test, with a score of 70% or better, and evaluation. The estimated time for completion of this activity is one hour. To receive a certificate, participants must demonstrate mastery of the presented material via the post-test. Participants are allowed to take the post-test multiple times.

Jointly provided by the Potomac Center for Medical Education and Rockpointe


This program is supported by an independent educational grant from Eisai, Inc.


PCME Privacy Policy